| Study Period | 2021 - 2030 |
| Market Size (2025) | USD 63.89 Billion |
| Market Size (2030) | USD 138.88 Billion |
| CAGR (2025 - 2030) | 16.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
mRNA Vaccine and Therapeutics Market Analysis
The mRNA Vaccines and Therapeutics Market size is estimated at USD 63.89 billion in 2025, and is expected to reach USD 138.88 billion by 2030, at a CAGR of 16.8% during the forecast period (2025-2030).
The mRNA vaccines and therapeutics industry is experiencing a transformative phase characterized by significant technological advancements and expanding applications beyond traditional vaccine development. Major pharmaceutical companies are increasingly investing in state-of-the-art manufacturing facilities and research centers to capitalize on the versatility of mRNA technology. This shift is evidenced by Eli Lilly and Company's substantial investment of USD 700 million in February 2022 to establish an RNA-based research and development facility at the Port of Boston, demonstrating the industry's commitment to advancing mRNA capabilities.
The market landscape is being reshaped by strategic collaborations and partnerships between biotechnology companies and research institutions, focusing on developing innovative therapeutic solutions. These partnerships are facilitating knowledge transfer and accelerating the development of novel molecular medicine and genetic therapeutics. The World Bank's approval of operations worth USD 10.1 billion in November 2022 to support vaccine rollout in 78 countries has significantly strengthened the global infrastructure for mRNA vaccine development and distribution, creating a robust foundation for future growth.
The industry is witnessing a notable shift towards personalized medicine and targeted therapeutics, with mRNA technology playing a pivotal role in developing customized treatment solutions. Pharmaceutical companies are expanding their research focus to include rare diseases, cancer therapeutics, and autoimmune conditions, leveraging the flexibility and precision of mRNA platforms. This diversification is supported by advanced manufacturing capabilities and improved delivery systems, enabling more efficient and effective therapeutic applications in nucleic acid therapeutics.
The market is characterized by increasing automation and digitalization in manufacturing processes, leading to enhanced production efficiency and quality control. According to the CDC's December 2022 update, the high prevalence of influenza cases, with 113,482 cases reported in clinical laboratories during October 2022, demonstrates the ongoing need for rapid vaccine development capabilities. This has prompted manufacturers to adopt advanced production technologies and streamlined processes to meet varying demand patterns while maintaining stringent quality standards.
mRNA Vaccine and Therapeutics Market Trends
SOARING DEMAND FOR NEW VACCINES AND THERAPEUTICS
The growing demand for genetic vaccines and genetic therapeutics is primarily driven by their versatility in addressing multiple diseases and conditions. The technology's ability to produce proteins that stimulate the body's immune system without using live viruses has made it an attractive option for vaccine development across various therapeutic areas. This is evidenced by the significant increase in clinical trials, with approximately 150 mRNA vaccine clinical trials registered in the United States involving biopharmaceuticals in 2022. The rapid advancement in this field has led to numerous breakthrough developments, particularly in areas previously challenging to target with traditional vaccine approaches.
The demand is further amplified by the expanding scope of mRNA applications beyond traditional vaccines. Major pharmaceutical companies and research institutions are actively pursuing mRNA-based solutions for various conditions, including cancer immunotherapy and rare diseases. For instance, in 2023, researchers from the Perelman School of Medicine at the University of Pennsylvania developed an experimental mRNA-based vaccine against all 20 known subtypes of the influenza virus, demonstrating the technology's potential in creating universal vaccines. Additionally, the increasing number of strategic collaborations between pharmaceutical companies and research institutions has accelerated the development pipeline, with companies like Moderna and Pfizer expanding their mRNA platforms to address unmet medical needs across multiple therapeutic areas.
Understand The Key Trends Shaping This Market
Download PDF
RISING CHRONIC AND INFECTIOUS DISEASES
The escalating prevalence of chronic and infectious diseases worldwide has become a significant driver for the mRNA vaccines and therapeutics market. According to the American Cancer Society's Cancer Facts & Figures 2022, an estimated 1.9 million new cancer cases were diagnosed in the United States, highlighting the urgent need for innovative therapeutic approaches. The global burden of infectious diseases also remains substantial, with the Minority of HIV/AIDS Fund reporting approximately 37.6 million people living with HIV worldwide, including 35.9 million adults and 1.7 million children, creating a pressing demand for effective preventive solutions.
The increasing incidence of various types of cancer and autoimmune conditions has spurred research into nucleic acid therapeutics. This is particularly evident in the development of personalized cancer vaccines and treatments for rare diseases. The rise in infectious diseases has also led to expanded research initiatives, with organizations like the National Institute of Allergy and Infectious Diseases (NIAID) launching new clinical trials for various conditions. For example, in 2023, multiple research institutions initiated trials for mRNA-based vaccines targeting diseases such as influenza, malaria, and other emerging infectious diseases, demonstrating the technology's potential in addressing both existing and emerging health challenges.
INCREASING R&D INVESTMENTS BY GOVERNMENT AND MARKET PLAYERS
Government organizations and private companies are making substantial investments in mRNA technology research and development, recognizing its potential to revolutionize disease prevention and treatment. The scale of investment is exemplified by significant government initiatives, such as the US President's Malaria Initiative's investment of USD 770 million to combat malaria, and the Canadian government's investment of up to USD 199.16 million in Resilience Biotechnologies Inc. for expanding manufacturing capabilities for various vaccines and therapeutics using new technologies like mRNA. These investments are crucial in advancing the field and enabling the development of next-generation therapeutic solutions.
The private sector's commitment to mRNA technology development is equally substantial, with pharmaceutical companies establishing dedicated research centers and forming strategic partnerships. For instance, in 2023, several major pharmaceutical companies announced significant investments in mRNA research facilities and manufacturing capabilities. These investments extend beyond traditional vaccine development to include novel therapeutic applications in oncology, rare diseases, and autoimmune conditions. The collaboration between academic institutions and industry players has also intensified, with universities receiving substantial grants for mRNA research, such as the establishment of RNA Centers of Excellence and Training Academies to support the development of new therapies and vaccines. This commitment underscores the growing importance of molecular medicine and genetic medicine in the future of healthcare.
Segment Analysis: By Product Type
Vaccines Segment in mRNA Vaccines and Therapeutics Market
The vaccines segment dominates the global mRNA vaccines and therapeutics market, commanding approximately 99% market share in 2024. This substantial market presence is primarily driven by the increasing demand for new vaccines to combat various infectious diseases and the growing research and development investments by government organizations and pharmaceutical companies. The segment's growth is further supported by the rising prevalence of chronic and infectious diseases worldwide, coupled with expanding applications in cancer treatment and autoimmune disorders. Major pharmaceutical companies are actively developing mRNA-based vaccines for various conditions, including influenza, HIV, and cancer, which continues to strengthen this segment's market position. The segment's dominance is also reinforced by established manufacturing infrastructure and distribution networks, along with favorable regulatory support for vaccine development and commercialization.
Therapeutics Segment in mRNA Vaccines and Therapeutics Market
The therapeutics segment is emerging as the fastest-growing segment in the mRNA vaccines and therapeutics market, with a projected growth rate of approximately 46% during 2024-2029. This remarkable growth is driven by increasing research and development activities in mRNA-based therapeutics for various diseases, including cancer, rare genetic disorders, and autoimmune conditions. The segment encompasses several promising areas including monoclonal antibodies, gene therapy, cell therapy, and protein replacement therapy, with each contributing to the segment's rapid expansion. Significant investments in research and development, coupled with technological advancements in mRNA delivery systems, are accelerating the development of novel therapeutic applications. The growing pipeline of mRNA-based therapeutic candidates and increasing clinical trials across various disease areas are further propelling this segment's growth trajectory.
Segment Analysis: By Application
Infectious Diseases Segment in mRNA Vaccines and Therapeutics Market
The infectious diseases segment dominates the global mRNA vaccines and therapeutics market, commanding approximately 99% of the market share in 2024. This substantial market dominance is primarily attributed to the increasing prevalence of various infectious diseases worldwide and the growing demand for effective preventive measures. The segment's growth is further supported by extensive research and development activities focused on developing mRNA-based solutions for emerging infectious diseases. Major pharmaceutical companies and research institutions are actively investing in developing innovative mRNA vaccines targeting various infectious diseases, including influenza, HIV, and other viral infections. The segment's robust performance is also bolstered by increasing government initiatives and funding support for vaccine development programs across different regions.
Autoimmune Diseases Segment in mRNA Vaccines and Therapeutics Market
The autoimmune diseases segment is emerging as the fastest-growing segment in the mRNA vaccines and therapeutics market, with a projected growth rate of approximately 52% during the forecast period 2024-2029. This remarkable growth is driven by increasing research activities in developing mRNA-based treatments for various autoimmune conditions. The segment is witnessing significant advancement in clinical trials and therapeutic developments, particularly in treating conditions such as multiple sclerosis and rheumatoid arthritis. Pharmaceutical companies are increasingly focusing on developing targeted mRNA therapies that can modulate the immune response in autoimmune conditions, offering more effective and personalized treatment options. The segment's growth is further supported by rising investments in research and development, along with increasing collaborations between biotechnology companies and research institutions.
Remaining Segments in mRNA Vaccines and Therapeutics Market by Application
The cancer and other therapeutic segments represent important growth areas in the mRNA vaccines and therapeutics market. The cancer segment is particularly noteworthy for its focus on developing personalized cancer vaccines and immunotherapies using mRNA technology. This segment is witnessing significant developments in targeting various types of cancers through innovative mRNA-based approaches. The 'others' segment encompasses various applications including cardiovascular diseases, genetic disorders, and other therapeutic areas where mRNA technology shows promising potential. These segments are characterized by ongoing research activities and clinical trials aimed at expanding the application scope of mRNA technology beyond infectious diseases and autoimmune conditions.
Segment Analysis: By End User
Hospitals and Clinics Segment in mRNA Vaccines and Therapeutics Market
The hospitals and clinics segment dominates the global mRNA vaccines and therapeutics market, commanding approximately 99% of the total market share in 2024. This substantial market presence is attributed to the segment's crucial role in vaccine administration and therapeutic treatments. The segment's dominance is reinforced by the increasing number of clinical trials involving hospitals and clinics, alongside the systematic distribution of vaccines through these healthcare facilities. The growing collaboration between pharmaceutical companies and healthcare institutions for vaccine development and administration has further strengthened this segment's position. Additionally, hospitals and clinics serve as primary points of contact for patient care and treatment, making them essential channels for mRNA vaccine distribution and administration. The segment's growth is also supported by robust healthcare infrastructure and the presence of skilled healthcare professionals capable of handling specialized therapeutic treatments.
Others Segment in mRNA Vaccines and Therapeutics Market
The others segment, which primarily consists of research laboratories and academic organizations, is experiencing significant developments despite its smaller market share. This segment plays a vital role in advancing nucleic acid therapeutics and genetic medicine through extensive research and development activities. The segment's growth is driven by increasing funding for research initiatives and growing partnerships between academic institutions and pharmaceutical companies. Research laboratories and academic organizations are actively involved in developing novel mRNA vaccines and therapeutics, contributing to technological innovations in the field. The segment benefits from government support and investments in research infrastructure, enabling the exploration of new applications for mRNA technology. Furthermore, these institutions serve as crucial testing grounds for new therapeutic approaches and play a significant role in conducting preliminary studies before clinical trials.
mRNA Vaccines and Therapeutics Market Geography Segment Analysis
mRNA Vaccines and Therapeutics Market in North America
The North American mRNA vaccines and therapeutics market encompasses three major countries: the United States, Canada, and Mexico. The region has established itself as a crucial market due to its advanced healthcare infrastructure, significant research and development activities, and the presence of major pharmaceutical companies. The market in this region is characterized by high healthcare expenditure, strong regulatory frameworks, and an increasing focus on innovative therapeutic solutions. The presence of well-established biopharmaceutical companies and increasing research collaborations have further strengthened the market position of North America in the global landscape.
mRNA Vaccines and Therapeutics Market in United States
The United States dominates the North American mRNA vaccine market with approximately 76% market share in the region. The country's market leadership is attributed to factors such as increasing incidences of chronic diseases, the presence of well-established biopharmaceutical companies, and an increase in biotech companies. The US market benefits from substantial research and development investments, advanced healthcare infrastructure, and a supportive regulatory environment. The country has witnessed significant developments in mRNA technology applications, particularly in areas such as cancer treatment and infectious diseases. The presence of major pharmaceutical companies and research institutions continues to drive innovation and market growth in the United States.
mRNA Vaccines and Therapeutics Market in Canada
Canada emerges as the fastest-growing market in North America with a forecasted growth rate of approximately -19% during 2024-2029. The country's market is driven by increasing healthcare expenditure, growing research activities, and rising awareness about innovative therapeutic solutions. Canada's healthcare system's strong focus on preventive care and the government's support for biotechnology research has created favorable conditions for market growth. The country has been actively involved in developing mRNA-based solutions for various diseases, supported by collaborations between academic institutions and pharmaceutical companies. The Canadian market shows promising potential for future growth, particularly in areas of personalized medicine and innovative therapeutic approaches.
mRNA Vaccines and Therapeutics Market in Europe
The European mRNA vaccines and therapeutics market comprises several key countries, including Germany, the United Kingdom, France, Italy, and Spain. The region has demonstrated significant advancement in mRNA technology development and applications. Europe's market is characterized by robust research infrastructure, strong healthcare systems, and supportive regulatory frameworks. The presence of major pharmaceutical companies and research institutions has facilitated continuous innovation and development in the field. The region's collaborative approach to healthcare research and development has fostered numerous partnerships between academic institutions, biotech companies, and pharmaceutical firms.
mRNA Vaccines and Therapeutics Market in Germany
Germany leads the European RNA therapeutics market with approximately 23% market share in the region. The country's dominant position is supported by its advanced healthcare infrastructure, significant research and development investments, and the presence of key market players. Germany's strong focus on biotechnology research and development has created a favorable environment for mRNA technology advancement. The country's healthcare system's emphasis on innovative therapeutic solutions and the presence of world-class research institutions have contributed to its market leadership. German pharmaceutical companies have been at the forefront of mRNA technology development, particularly in areas of vaccine development and personalized medicine.
mRNA Vaccines and Therapeutics Market in Spain
Spain demonstrates the highest growth potential in the European region with a forecasted growth rate of approximately -17% during 2024-2029. The country's market is driven by increasing investment in healthcare infrastructure, growing research activities, and rising adoption of innovative therapeutic solutions. Spain has shown significant progress in developing mRNA-based treatments, particularly in areas of infectious diseases and cancer therapy. The country's healthcare system's focus on preventive care and the government's support for biotechnology research has created favorable conditions for market growth. Spanish research institutions and pharmaceutical companies have been actively involved in developing innovative mRNA-based solutions.
mRNA Vaccines and Therapeutics Market in Asia-Pacific
The Asia-Pacific mRNA vaccines and therapeutics market encompasses major economies, including China, Japan, India, Australia, and South Korea. The region has shown remarkable progress in adopting and developing mRNA technology, supported by increasing healthcare expenditure and growing research activities. The market is characterized by rapid technological advancement, increasing healthcare awareness, and growing investment in biotechnology research. The region's large patient population and increasing focus on innovative therapeutic solutions have created significant opportunities for market growth.
mRNA Vaccines and Therapeutics Market in China
China dominates the Asia-Pacific RNA therapeutics market, demonstrating strong market presence through its extensive healthcare infrastructure and significant research capabilities. The country's leadership in the regional market is supported by substantial government investments in biotechnology research and development. China's large patient population and increasing focus on innovative therapeutic solutions have created a robust market environment. The country has made significant strides in developing domestic mRNA technology capabilities, supported by collaborations between research institutions and pharmaceutical companies.
mRNA Vaccines and Therapeutics Market in Australia
Australia emerges as the fastest-growing market in the Asia-Pacific region, showing significant potential in mRNA technology development and applications. The country's growth is driven by its strong research infrastructure, supportive regulatory environment, and increasing focus on innovative therapeutic solutions. Australia's healthcare system's emphasis on advanced medical technologies and the government's support for biotechnology research has created favorable conditions for market growth. The country has been actively involved in developing mRNA-based solutions through collaborations between academic institutions and pharmaceutical companies.
mRNA Vaccines and Therapeutics Market in Middle East & Africa
The Middle East & Africa market for mRNA vaccines and therapeutics encompasses various countries, with the GCC and South Africa being key markets. The region has shown increasing adoption of mRNA technology, supported by growing healthcare infrastructure and rising investment in biotechnology research. The market is characterized by improving healthcare systems, increasing awareness about innovative therapeutic solutions, and growing government support for healthcare development. Within the region, the GCC emerges as the largest market while South Africa shows the fastest growth potential, driven by increasing healthcare expenditure and growing research activities.
mRNA Vaccines and Therapeutics Market in South America
The South American mRNA vaccines and therapeutics market, primarily represented by Brazil and Argentina, has shown significant potential for growth and development. The region has demonstrated increasing interest in mRNA technology applications, supported by growing healthcare infrastructure and rising investment in biotechnology research. The market is characterized by improving healthcare systems, increasing awareness about innovative therapeutic solutions, and growing government support for healthcare development. Brazil emerges as the largest market in the region, while Argentina shows promising growth potential, driven by increasing healthcare expenditure and growing research activities in the field of mRNA technology.
Get Analysis on Important Geographic Markets
Download PDF
mRNA Vaccine and Therapeutics Industry Overview
Top Companies in mRNA Vaccines and Therapeutics Market
The mRNA vaccines and therapeutics market is characterized by intense innovation and strategic developments from key players including Pfizer, Moderna, BioNTech, AstraZeneca, GlaxoSmithKline, and CureVac. Companies are heavily investing in research and development to expand their mRNA technology platforms and product pipelines beyond COVID-19 vaccines into areas like cancer therapeutics and rare diseases. Strategic collaborations between pharmaceutical giants and biotechnology specialists have become increasingly common to leverage complementary capabilities and accelerate development timelines. Manufacturing capacity expansion through new facility investments and contract manufacturing partnerships demonstrates the industry's focus on operational scalability. Geographic expansion, particularly in emerging markets, coupled with continuous efforts to improve product stability and distribution capabilities, highlights the sector's commitment to broader market access and commercial growth.
Consolidated Market with Strong Innovation Focus
The nucleic acid therapeutics market exhibits a relatively consolidated structure dominated by large pharmaceutical conglomerates and specialized biotechnology firms with strong research capabilities. Major pharmaceutical companies leverage their extensive commercial infrastructure and global reach while partnering with innovative biotech firms that possess specialized mRNA technology platforms. The market has witnessed significant consolidation through strategic partnerships, licensing agreements, and collaborative research arrangements rather than traditional mergers and acquisitions, as companies prioritize technology access and development capabilities over immediate market share gains.
The competitive dynamics are shaped by substantial barriers to entry, including complex intellectual property landscapes, specialized manufacturing requirements, and stringent regulatory oversight. Early market entrants have established strong positions through pioneering technology platforms and extensive patent portfolios. Regional players, particularly in emerging markets, are gradually building capabilities through technology transfers and government support, though global leaders maintain significant advantages in terms of technology sophistication and commercial scale.
Innovation and Adaptability Drive Future Success
Success in the mRNA vaccines and therapeutics market increasingly depends on companies' ability to diversify their product pipelines beyond infectious diseases while maintaining technological leadership through continuous platform innovation. Established players must focus on expanding therapeutic applications, improving product stability, and reducing manufacturing costs to maintain their competitive advantage. Building robust clinical development capabilities, establishing strategic partnerships across the value chain, and maintaining strong relationships with regulatory authorities are becoming critical success factors.
Market contenders can gain ground by focusing on specialized therapeutic areas, developing novel delivery technologies, or addressing unmet needs in specific geographic markets. The industry faces moderate substitution risk from traditional vaccine technologies and emerging therapeutic approaches, necessitating clear value demonstration through clinical outcomes and cost-effectiveness. Regulatory frameworks continue to evolve, particularly around manufacturing standards and clinical development requirements, making regulatory expertise and compliance capabilities essential for long-term success. Companies must also address end-user concerns about novel technology adoption through comprehensive education and engagement strategies. The integration of molecular medicine and genetic medicine into product development is crucial for addressing complex diseases and advancing therapeutic innovations.
mRNA Vaccine and Therapeutics Market Leaders
-
Pfizer Inc.
-
Moderna, Inc.
-
BioNTech SE
-
GlaxoSmithKline
-
Daiichi Sankyo
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
mRNA Vaccine and Therapeutics Market News
- November 2022: Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals aged 18 years and older. Health Canada previously authorized similar bivalent booster doses containing Omicron BA.1 or BA.4/5 variants from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) in September and October of 2022, respectively.
- October 2022: Moderna Inc. reported that it had received emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents aged 6 to 17 years.
mRNA Vaccine and Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Soaring Demand for New Vaccines and Therapeutics
- 4.2.2 Rising Chronic and Infectious Diseases
- 4.2.3 Increasing R&D Investments by the Government and Market Players
-
4.3 Market Restraints
- 4.3.1 Strict Legal Requirements and Frameworks
- 4.3.2 High Price Associated with mRNA-based Vaccines and Therapeutics
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Vaccine Type
- 5.1.1 Self-amplifying mRNA-based Vaccines
- 5.1.2 Conventional Non-amplifying mRNA-based Vaccines
-
5.2 By Application
- 5.2.1 Cancer
- 5.2.2 Infectious Diseases
- 5.2.3 Autoimmune Diseases
- 5.2.4 Other Applications
-
5.3 By Treatment Type
- 5.3.1 Monoclonal Antibody
- 5.3.2 Gene Therapy
- 5.3.3 Cell Therapy
- 5.3.4 Other Treatment Types
-
5.4 By End User
- 5.4.1 Research Laboratories and Organizations
- 5.4.2 Hospitals and Clinics
- 5.4.3 Other End Users
-
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 Moderna Inc.
- 6.1.3 BioNTech SE
- 6.1.4 Daiichi Sankyo
- 6.1.5 GlaxoSmithKline
- 6.1.6 Arcturus Therapeutics Inc.
- 6.1.7 CureVac
- 6.1.8 AIM Vaccine
- 6.1.9 Ethris GmbH
- 6.1.10 Sino Biopharmaceutical Limited (pHion Therapeutics Ltd)
- 6.1.11 AstraZeneca
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now
mRNA Vaccine and Therapeutics Industry Segmentation
As per the scope of the report, mRNA vaccines and therapeutics enable the combination of the desirable immunological properties. These are prepared in laboratories using mammalian cells and are injected into the body of the target to trigger virus-detecting immune sensors and produce viral antigen proteins within the cells. This enhances the body's immune system by improving B- and T-cell responses.
The mRNA vaccines and therapeutics market is segmented by vaccine type (self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines), application (cancer, infectious diseases, autoimmune diseases, and other applications), treatment type (monoclonal antibody, gene therapy, cell therapy, and other treatment types), end user (research laboratories and organizations, hospitals and clinics, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Vaccine Type | Self-amplifying mRNA-based Vaccines | ||
| Conventional Non-amplifying mRNA-based Vaccines | |||
| By Application | Cancer | ||
| Infectious Diseases | |||
| Autoimmune Diseases | |||
| Other Applications | |||
| By Treatment Type | Monoclonal Antibody | ||
| Gene Therapy | |||
| Cell Therapy | |||
| Other Treatment Types | |||
| By End User | Research Laboratories and Organizations | ||
| Hospitals and Clinics | |||
| Other End Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
mRNA Vaccine and Therapeutics Market Research FAQs
How big is the mRNA Vaccines and Therapeutics Market?
The mRNA Vaccines and Therapeutics Market size is expected to reach USD 63.89 billion in 2025 and grow at a CAGR of 16.80% to reach USD 138.88 billion by 2030.
What is the current mRNA Vaccines and Therapeutics Market size?
In 2025, the mRNA Vaccines and Therapeutics Market size is expected to reach USD 63.89 billion.
Who are the key players in mRNA Vaccines and Therapeutics Market?
Pfizer Inc., Moderna, Inc., BioNTech SE, GlaxoSmithKline and Daiichi Sankyo are the major companies operating in the mRNA Vaccines and Therapeutics Market.
Which is the fastest growing region in mRNA Vaccines and Therapeutics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in mRNA Vaccines and Therapeutics Market?
In 2025, the North America accounts for the largest market share in mRNA Vaccines and Therapeutics Market.
What years does this mRNA Vaccines and Therapeutics Market cover, and what was the market size in 2024?
In 2024, the mRNA Vaccines and Therapeutics Market size was estimated at USD 53.16 billion. The report covers the mRNA Vaccines and Therapeutics Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the mRNA Vaccines and Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
mRNA Vaccines and Therapeutics Market Research
Mordor Intelligence brings extensive expertise in analyzing the rapidly evolving mRNA vaccines and therapeutics market. We offer comprehensive insights into advancements in molecular medicine and breakthrough developments in genetic medicine. Our detailed research covers the entire spectrum of nucleic acid therapeutics and genetic therapeutics. This provides stakeholders with crucial data on technological innovations, regulatory landscapes, and emerging opportunities. The analysis includes in-depth coverage of the RNA therapeutics market and mRNA vaccine market. We deliver actionable intelligence through an easy-to-download report PDF format.
Our research empowers stakeholders across the genetic vaccine development ecosystem with strategic insights and competitive intelligence. The report examines RNA therapeutics market size trends and growth projections. It also thoroughly analyzes nucleic acid therapeutics market dynamics. Industry participants gain access to detailed evaluations of therapeutic applications, manufacturing capabilities, and regional market dynamics. All information is presented in a comprehensive, downloadable format designed to support informed decision-making and strategic planning.
